Real-world evidence

Integrated solutions for vaccine innovation

With over 30 years of proven vaccine experience from pre-clinical to post-licensure, our global team understands the unique challenges faced by vaccine manufacturers. Prophylactic vaccine development differs from therapeutic development, and we offer specialized knowledge and services to optimize your program, providing regulatory insights, real-world evidence (RWE) proficiency, subject/patient-centered enrollment solutions, extensive economic modeling and and health technology assessment (HTA) / National Immunization Technical Advisory Group (NITAG) submission experience.



Why our team?

Tailored solutions
120+ vaccine-related real-world evidence and market access engagements

Comprehensive expertise
30+ years proven vaccine experience in **20+ indications**

Innovative approaches
Next-generation methodologies to support peri- and post-approval evidence-based solutions

Dedicated support
950+ Person integrated global team of real-world and market access specialists

Case Study 1: Driving vaccine market access with patient-centered evidence

A client investing in vaccines requiring fewer shots for multi-valent protection needed to understand patient-perceived value to develop an effective market access strategy.

Challenge:

Understand patient preferences for multi-valent vaccines and characterize differences between adolescent and parent/guardians' preferences.

Approach:

- Conducted a patient preference study to understand how adolescents and parent/guardians perceive the benefits of additional valency protection
- Performed a discrete choice experiment to elicit the importance of vaccine attributes, explore willingness to be vaccinated, and examine heterogeneity in predicted uptake among population groups

Impact:

The evidence informed market access and value strategy, highlighting the value of multi-valent vaccines and their ability to address unmet needs in vaccine coverage.

Case Study 2: Next-generation methodologies to support evidence-based vaccine solutions

The COVID-19 pandemic disrupted typical vaccine market access routes and created new decision makers and unpredictable health economic and market access (HEMA) requirements for emerging vaccines.

Challenge:

Urgently overcome pandemic-period vaccine market access challenges to ensure rapid patient access to our client's vaccine.

Approach:

- Stakeholder mapping and engagement to identify and understand the rapidly evolving market access pathways and HEMA evidence requirements
- Timely value messaging testing, value dossiers, payer Q&As, economic modeling, literature reviews, and indirect treatment comparisons to support NITAG and government decisions
- Optimization modeling to help governments allocate boosters effectively, minimizing hospitalizations and conserving healthcare resources

Impact:

Our solutions empowered informed decision-making, accelerated vaccine access, and optimized limited healthcare resources.

(Abbreviation - NITAG: National Immunization Technical Advisory Group)

Case Study 3: Site and data source feasibility assessment enhances efficiencies for vaccine post-marketing commitment study

Challenge:

Prospective observational study to assess vaccine effectiveness for a post-marketing commitment requiring systematic linkage of individualized patient data to vaccine records (e.g., national vaccine registry).

Approach:

- Innovative study design maximizing use of secondary data to optimize evidence generation and reduce research burden
- Developed and executed a unique diverse data feasibility assessment for sites and secondary data sources

Impact:

Optimized site selection and study design using secondary data sources to reduce research burden and increase confidence in robustness of critical variables.

Learn more at **ppd.com/rwe**